An observational study on the adherence to treatment guidelines of osteopenia

Journal of Women's Health

Volumn 18, Issue 6, 2009, Pages 873-881

  Buencamino, Maria Clarinda A ^a   Sikon, Andrea L ^a   Jain, Anil ^a   Thacker, Holly L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; LEVOTHYROXINE SODIUM; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIUM INTAKE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMALE; GOOD CLINICAL PRACTICE; HEALTH CENTER; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; OSTEOPENIA; PATIENT COUNSELING; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RETROSPECTIVE STUDY; VITAMIN SUPPLEMENTATION; WEIGHT BEARING;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COMBINED MODALITY THERAPY; COUNSELING; EXERCISE; FEMALE; HEALTH EDUCATION; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; VITAMIN D; WOMEN'S HEALTH;

EID: 67650260789     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.0897     Document Type: Article

References (42)

1. Thacker H, Richmond B. In rebuttal: Osteopenia is a useful diagnosis. Cleve Clin J Med 2006;73:34-38.
2. National Osteoporosis Foundation. Available at www.nof.org/ professionals/NOF-Clinicians-Guide.pdf Accessed November 16, 2006. Reaccessed February 22, 2008.
3. World Health Organization Scientific Group. Prevention and treatment of osteoporosis. WHO Technical Report Series 2003. Available at whqlibdoc.who.int/trs/WHO-TRS-921.pdf. Accessed March 12, 2007.
4. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006;13:340-367.
5. Mazanec D. Osteoporosis screening. Arch Intern Med 2004;164:1047-1048.
6. U.S. Preventive Services Task Force. Guide to clinical preventive services, 2nd ed. Baltimore, MD: Williams & Wilkins, 1996.
7. Wehren LE. Should a diagnosis of osteopenia trigger clinical action? Int J Fertil Womens Med 2003;48:117-121.
8. Derman R. Identifying the osteopenic patient and preventing worsening of the disease. Curr Womens Health Rep 2003;3:199-206.
9. Siris ES, Brenneman SK, Miller PD, et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: Results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004;19:1215-1220.
10. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporosis Int 2006;17:1404-1409.
11. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates in 2003. Endocrine Practice 2003;19:544-564.
12. Krakauer JC, Kleerekoper M. Borderline-low serum thyrotropin level is correlated with increased fasting urinary hydroxyproline excretion. Arch Intern Med 1992;152:360-364.
13. Department of Health and Human Services, Centers for Disease Control and Prevention. Alcohol and public health - General information on alcohol use and health, 2007. Available at www.cdc.gov/alcohol/quickstats/general-info.htm Accessed March 28, 2007.
14. Shoemaker L, Sikon A, Jain A, et al. Repeat dual-energy x-ray absorptiometry (DXA) resulting from reminder letters for women with a baseline abnormal DXA. J Clin Densitom 2007;10:21-24.
15. Miller PD. Should low bone mass be treated? Int J Fertil Womens Med 2005;50:83-87.
16. Cram P, Schlechte J, Rosenthal GE, Christensen AJ. Patient preference for being informed of their DXA scan results. J Clin Densitom 2004;7:275-280.
17. Sikon A, Thacker H, Carey J, Deal C, Licata AA. Secondary osteoporosis: Are we recognizing it?. J Womens Health 2006;15:1174-1183.
18. Kanis JA, Johnell A, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis Int 2001;12:989-995.
19. Kanis JA, Johnell O, Oden H, Johansson H. FRAX™ and the assessment of fracture probability in men and women from the U.K. Osteoporosis Int 2008;19:385-397.
20. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 2005;193:2257-2264.
21. Yates AA, Schlicker SA, Suitor CW. Dietary Reference Intakes: The new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699-706.
22. Kelley GA, Kelley KS, Tran ZV. Exercise and lumbar spine bone mineral density in postmenopausal women: A metaanalysis of individual patient data. J Gerontol A Biol Sci Med Sci 2002;57:599-604.
23. Kronhed AC, Moller M. Effects of physical exercise on bone mass, balance skill and aerobic capacity in women and men with low bone mineral density, after one year of training - A prospective study. Scand J Med Sci Sports 1998;8:290-298.
24. Iwamoto J, Takeda T, Sato Y. Effect of treadmill exercise on bone mass in female rats. Exp Anim 2005;54:1-6.
25. Lui PPY, Qin L, Chan KM. Tai Chi Chun exercises in enhancing bone mineral density in active seniors. Clin Sports Med 2008;27:75-86.
26. Qin L, Choy WY, Leung KS, et al. Beneficial effects of regular Tai Chi exercise on musculoskeletal system. J Bone Miner Metab 2005;23:186-190.
27. Qin L, Au SK, Choy WY, et al. Regular Tai Chi Chun exercise may retard bone loss in postmenopausal women - A case-control study. Arch Phys Med Rehabil 2002;83:1355-1359.
28. Chan KM, Qin L, Lau MC, et al. A randomized prospective study of the effects of Tai Chi Chun exercise on bone mineral density in postmenopausal women. Arch Phys Med Rehabil 2004;85:717-722.
29. Oncken C, Prestwood K, Kleppinger A, Wang Y, Cooney J, Raisz L. Impact of smoking cessation on bone mineral density in postmenopausal women. J Womens Health 2006;15:1141-1150.
30. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1531-1541.
31. McClung MR, Geusen P, Miller PD, et al. Effect of rise-dronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340.
32. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis Int 2000;11:83-91.
33. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
34. Ettinger B, Black DM, Mitlack BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene (MORE) Investigators. JAMA 1999;282:637-645.
35. Cauley JA, Robbins J, Chen Z. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
36. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676.
37. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 2008;15:584-603.
38. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmen-opausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000;109:267-276.
39. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
40. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-439.
41. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283:1318-1321.
42. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2026.